Literature DB >> 15365127

Beta-synuclein gene alterations in dementia with Lewy bodies.

H Ohtake1, P Limprasert, Y Fan, O Onodera, A Kakita, H Takahashi, L T Bonner, D W Tsuang, I V J Murray, V M-Y Lee, J Q Trojanowski, A Ishikawa, J Idezuka, M Murata, T Toda, T D Bird, J B Leverenz, S Tsuji, A R La Spada.   

Abstract

OBJECTIVE: To determine whether mutations in the genes for alpha-synuclein or beta-synuclein are responsible for dementia with Lewy bodies (DLB), a disorder closely related to Parkinson disease (PD).
METHODS: The authors ascertained 33 sporadic cases of DLB and 10 kindreds segregating DLB. DNA samples from the 43 index cases were screened for alterations in the genes for alpha-synuclein and beta-synuclein, as alpha-synuclein alterations cause PD and beta-synuclein may modulate alpha-synuclein aggregation and neurotoxicity.
RESULTS: Two amino acid alterations were identified in unrelated DLB index cases: a valine to methionine substitution at codon 70 (V70M) and a proline to histidine substitution at codon 123 (P123H), both in the beta-synuclein gene. These amino acid substitutions occur at conserved residues in highly conserved regions of the beta-synuclein protein. Screening of at least 660 chromosomes from control subjects matched to the patients' population groups failed to identify another V70M or P123H allele. Cosegregation analysis of an extended pedigree segregating the P123H beta-synuclein alteration suggested that it is a dominant trait with reduced penetrance or a risk factor polymorphism. Histopathology and immunohistochemistry analysis of index case brain sections revealed widespread Lewy body pathology and alpha-synuclein aggregation without evidence of beta-synuclein aggregation.
CONCLUSION: Mutations in the beta-synuclein gene may predispose to DLB.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365127      PMCID: PMC1808539          DOI: 10.1212/01.wnl.0000139870.14385.3c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

2.  Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion.

Authors:  H OKAZAKI; L E LIPKIN; S M ARONSON
Journal:  J Neuropathol Exp Neurol       Date:  1961-04       Impact factor: 3.685

Review 3.  The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders.

Authors:  K K Chung; V L Dawson; T M Dawson
Journal:  Trends Neurosci       Date:  2001-11       Impact factor: 13.837

4.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.

Authors:  M Hashimoto; E Rockenstein; M Mante; M Mallory; E Masliah
Journal:  Neuron       Date:  2001-10-25       Impact factor: 17.173

6.  Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease.

Authors:  E Rockenstein; L A Hansen; M Mallory; J Q Trojanowski; D Galasko; E Masliah
Journal:  Brain Res       Date:  2001-09-28       Impact factor: 3.252

7.  Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.

Authors:  P J Kahle; M Neumann; L Ozmen; V Muller; H Jacobsen; A Schindzielorz; M Okochi; U Leimer; H van Der Putten; A Probst; E Kremmer; H A Kretzschmar; C Haass
Journal:  J Neurosci       Date:  2000-09-01       Impact factor: 6.167

8.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

Review 9.  Synucleinopathies: clinical and pathological implications.

Authors:  J E Galvin; V M Lee; J Q Trojanowski
Journal:  Arch Neurol       Date:  2001-02

Review 10.  Diffuse Lewy body disease.

Authors:  K Kosaka
Journal:  Neuropathology       Date:  2000-09       Impact factor: 1.906

View more
  54 in total

1.  A pH-dependent switch promotes β-synuclein fibril formation via glutamate residues.

Authors:  Gina M Moriarty; Michael P Olson; Tamr B Atieh; Maria K Janowska; Sagar D Khare; Jean Baum
Journal:  J Biol Chem       Date:  2017-07-14       Impact factor: 5.157

2.  Twin pairs discordant for neuropathologically confirmed Lewy body dementia.

Authors:  C Sheei-Meei Wang; J R Burke; D C Steffens; C M Hulette; J C S Breitner; B L Plassman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-05       Impact factor: 10.154

Review 3.  Recent advances in the genetics of dementia with lewy bodies.

Authors:  Vincenzo Bonifati
Journal:  Curr Neurol Neurosci Rep       Date:  2008-05       Impact factor: 5.081

Review 4.  Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders.

Authors:  Dena A M Amer; G Brent Irvine; Omar M A El-Agnaf
Journal:  Exp Brain Res       Date:  2006-05-30       Impact factor: 1.972

Review 5.  Genetics of synucleins in neurodegenerative diseases.

Authors:  José Brás; Elizabeth Gibbons; Rita Guerreiro
Journal:  Acta Neuropathol       Date:  2020-08-01       Impact factor: 17.088

6.  New brain-specific beta-synuclein isoforms show expression ratio changes in Lewy body diseases.

Authors:  Katrin Beyer; Ana M Munoz-Marmol; Carolina Sanz; Ruth Marginet-Flinch; Isidro Ferrer; Aurelio Ariza
Journal:  Neurogenetics       Date:  2011-12-29       Impact factor: 2.660

7.  The function of α-synuclein.

Authors:  Jacob T Bendor; Todd P Logan; Robert H Edwards
Journal:  Neuron       Date:  2013-09-18       Impact factor: 17.173

Review 8.  Interactions between the Intrinsically Disordered Proteins β-Synuclein and α-Synuclein.

Authors:  Jonathan K Williams; Xue Yang; Jean Baum
Journal:  Proteomics       Date:  2018-09-09       Impact factor: 3.984

Review 9.  The neurogenetics of atypical parkinsonian disorders.

Authors:  Brent L Fogel; Mary C Clark; Daniel H Geschwind
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 10.  Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Authors:  Masayo Fujita; Akio Sekigawa; Kazunari Sekiyama; Shuei Sugama; Makoto Hashimoto
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.